Dacomitinib Monohydrate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Dacomitinib Monohydrate |
| DrugBank ID | DB11963 |
| Brand Names (EU) | Vizimpro |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 97.79% |
Approved Indication (EMA)
Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | rheumatoid arthritis | 97.79% | DL |
| 2 | homozygous familial hypercholesterolemia | 96.92% | DL |
| 3 | brachydactyly-syndactyly syndrome | 96.78% | DL |
| 4 | pulmonary hypertension | 96.51% | DL |
| 5 | nephrogenic syndrome of inappropriate antidiuresis | 96.44% | DL |
| 6 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | 96.44% | DL |
| 7 | kyphoscoliotic heart disease | 96.18% | DL |
| 8 | multiple endocrine neoplasia | 96.18% | DL |
| 9 | amyotrophic lateral sclerosis | 95.12% | DL |
| 10 | leprosy | 94.95% | DL |
| 11 | Prinzmetal angina | 94.92% | DL |
| 12 | migraine disorder | 94.81% | DL |
| 13 | hyperthyroidism | 94.70% | DL |
| 14 | female breast carcinoma | 94.51% | DL |
| 15 | Mills syndrome | 94.50% | DL |
| 16 | amyotrophic lateral sclerosis, susceptibility to | 94.48% | DL |
| 17 | amyotrohpic lateral sclerosis type 22 | 94.46% | DL |
| 18 | migraine with brainstem aura | 94.39% | DL |
| 19 | resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta | 94.28% | DL |
| 20 | migraine with or without aura, susceptibility to | 94.24% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.